ILLUCCIX

ILLUCCIX- kit for the preparation of gallium ga 68 gozetotide injection
Telix Pharmaceuticals US Inc.

1 INDICATIONS AND USAGE

ILLUCCIX®, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

2 DOSAGE AND ADMINISTRATION

2.1 Radiation Safety — Drug Handling

Handle Gallium Ga 68 Gozetotide Injection with appropriate safety measures to minimize radiation exposure [ see Warnings and Precautions ( 5.2) ]. Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Gallium Ga 68 Gozetotide Injection.

Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

2.2 Recommended Dosage and Administration Instructions

Recommended Dosage

In adults, the recommended amount of radioactivity to be administered for PET is 111 MBq to 259 MBq (3 mCi to 7 mCi) administered as an intravenous bolus injection.

Administration

  • Use aseptic technique and radiation shielding when withdrawing and administering Gallium Ga 68 Gozetotide Injection.
  • Calculate the necessary volume to administer based on calibration time and required dose.
  • Inspect Gallium Ga 68 Gozetotide Injection visually for particulate matter and discoloration before administration. Only use solutions that are clear, colorless or at most slightly yellow, and without visible particles.
  • Gallium Ga 68 Gozetotide Injection may be diluted with sterile 0.9% Sodium Chloride Injection, USP.
  • Assay the final dose in a dose calibrator immediately before administration to the patient.
  • After injection of Gallium Ga 68 Gozetotide Injection, administer an intravenous flush of sterile 0.9% Sodium Chloride Injection, USP to ensure full delivery of the dose.
  • Dispose of any unused drug in a safe manner in compliance with applicable regulations.
  • Unless contraindicated, a diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection to potentially decrease artifact from radiotracer accumulation in the urinary bladder and ureters.

2.3 Patient Preparation Prior to PET Imaging

Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Gallium Ga 68 Gozetotide Injection and to continue to drink and void frequently following administration to reduce radiation exposure, particularly during the first hour after administration [see Warnings and Precautions ( 5.2)].

2.4 Drug Preparation

ILLUCCIX is supplied as a 3-vial kit in two different configurations [ see Dosage Forms and Strength (3)] for preparation of Gallium Ga 68 Gozetotide Injection with eluate from one of the following (see below for specific instructions for use with each Ga 68 source):

  • Cyclotron produced via GE FASTlab TM (Configuration A)
  • Eckert & Ziegler (EZAG) GalliaPharm ® Germanium 68/Gallium 68 (Ge 68/Ga 68) generator (Configuration A)
  • IRE Galli Eo® Ge 68/Ga 68 generator (Configuration B)

The Ge 68/Ga 68 generators and cyclotron are not supplied with ILLUCCIX.

Components of ILLUCCIX include:

  • Vial 1 (Gozetotide Vial) contains 25 mcg of gozetotide and 10 mcg of D-mannose (stabilizer) as a lyophilized powder.
  • Vial 2 (Acetate Buffer Vial) contains 150 mg anhydrous sodium acetate in HCl buffer.
  • Vial 3 (Sterile Vacuumed Reaction Vial) is a sterile, evacuated vial that serves as the collection vial for Ga 68 chloride and radiolabeling reaction.

Prepare Gallium Ga 68 Gozetotide Injection for intravenous injection according to the following aseptic procedure:

  1. Use suitable shielding to reduce radiation exposure.
  2. Wear waterproof gloves.
  3. If Ga 68 is generator produced, test the Ga 68 chloride eluate for Ge 68 breakthrough weekly by a suitable method according to manufacturer recommendations. Ge 68 breakthrough and other gamma emitting radionuclides should meet the specifications (≤0.001%) provided by the manufacturer. If Ga 68 is cyclotron produced, test for Ga 66 and Ga 67 (with specification of ≤2% combined total) when a new Zn 68 is introduced for manufacturing.
  4. Place a “radioactive” label on Vial 3 (Sterile Vacuumed Reaction Vial) with product name, lot number and date.
  5. Remove the vial cap from Vial 1, Vial 2 and Vial 3.
  6. Swab the top of each vial with alcohol to disinfect the surface and allow the top of each vial to dry.
  7. Note that to minimize any potential metallic contamination, the shortest possible needle should be used for the transfer of the gallium solution from the generator. The needle should be clean and dilute acid resistant.
  8. Use only plastic syringes for preparation and administration. Do not use syringes with rubber plungers.
  9. Note that prior to use of any vial, confirm the correct vial is being used by a visual check of the vial label.
  10. Follow the specific reconstitution procedure below, dependent on Ga 68 source. Then continue with the dilution and radiosynthesis procedure below.

Preparation with Cyclotron Produced Ga 68 via GE FASTlab

Collection of Gallium Ga 68 Chloride

  1. After purification by the FASTlab, the Ga 68 chloride solution is passed through a sterile filter and into the cassette product vial automatically by the FASTlab.
  2. Pierce Vial 3 (Sterile Vacuumed Reaction Vial) with a sterile needle connected to a 0.2 micron sterile vented filter (not supplied) to maintain atmospheric pressure within the vial during the reconstitution process.
  3. Aseptically transfer 5 mL of Ga 68 chloride solution into Vial 3.

Reconstitution and Radiolabeling Reaction Procedure

  1. Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration A) and draw up the contents of the vial (2.5 mL).
  2. Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial).
  3. Gently swirl Vial 1 to ensure the product is thoroughly dissolved.
  4. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the contents of the vial.
  5. Transfer the contents of the 10 mL syringe to the reaction Vial 3 containing the Ga 68 chloride.
  6. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)) .
  7. Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result.
  8. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control.
  9. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles.
  10. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use.
  11. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL.

Preparation with Eckert & Ziegler GalliaPharm Generator

Collection of Gallium Ga 68 Chloride

  1. Prepare a syringe containing 5 mL of sterile ultrapure 0.1M HCl provided with the GalliaPharm Generator for elution.
  2. Pierce Vial 3 (Sterile Vacuumed Reaction Vial) with a sterile needle connected to a 0.2- micron sterile vented filter (not supplied) to maintain atmospheric pressure within the vial during the reconstitution process.
  3. Connect the male luer of the outlet line of the GalliaPharm generator to a sterile needle.
  4. Connect Vial 3 directly to the outlet line of the GalliaPharm generator by pushing the needle through the rubber septum and place the vial in a radiation shielded container.
  5. Elute the generator directly with the 5 mL 0.1 M HCl from step 1 into Vial 3 according to the instructions for use of the GalliaPharm generator that are supplied by Eckert & Ziegler. Perform the elution manually or by means of a pump. Collect 5 mL of eluate.
  6. At the end of the elution, disconnect the generator from Vial 3 by removing the needle from the rubber septum.

Reconstitution and Radiolabeling Reaction Procedure

  1. Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration A) and draw up the contents of the vial (2.5 mL).
  2. Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial).
  3. Gently swirl Vial 1 to ensure the product is thoroughly dissolved.
  4. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the contents of the vial.
  5. Transfer the contents of the 10 mL syringe to Vial 3 (Sterile Vacuumed Reaction Vial) containing the Ga 68 chloride.
  6. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)).
  7. Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result.
  8. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control.
  9. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles.
  10. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use.
  11. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL.

Preparation with IRE Galli Eo Generator

Collection of Gallium Ga 68 Chloride

  1. Connect the male luer of the outlet line of the Galli Eo generator to a sterile needle.
  2. Elute the generator directly into Vial 3 (Sterile Vacuumed Reaction Vial) according to the instructions for use of the Galli Eo generator that are supplied by IRE. Collect 1.1 mL of eluate.
  3. At the end of the elution, disconnect the generator from Vial 3 by removing the needle from the rubber septum.

Reconstitution and Radiolabeling Reaction Procedure

  1. Insert a sterile 10 mL syringe with a needle into Vial 2 (Acetate Buffer Vial Configuration B) and draw up the contents of the vial.
  2. Inject the contents of the 10 mL syringe into Vial 1 (Gozetotide Vial).
  3. Gently swirl Vial 1 to ensure the product is thoroughly dissolved.
  4. Insert a sterile 10 mL syringe with a needle into Vial 1 containing the dissolved gozetotide and draw up the contents of the vial (6.4 mL).
  5. Transfer the contents of the 10 mL syringe to the reaction Vial 3 containing the Ga 68 chloride.
  6. Wait for 5 minutes for radiolabeling to take place at ambient temperature (25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)).
  7. Assay the whole vial containing the Gallium Ga 68 Gozetotide Injection for total radioactivity using a dose calibrator, calculate the radioactivity concentration and record the result.
  8. Perform the quality control of Gallium Ga 68 Gozetotide Injection according to the recommended methods in the Subsection 2.5 Specifications and Quality Control.
  9. Prior to use, visually inspect the solution behind a shielded screen for radioprotection purposes. Only use solutions that are clear without visible particles.
  10. Keep the vial containing the Gallium Ga 68 Gozetotide Injection upright in a radio-protective shield container at ambient temperature until use.
  11. After reconstitution and addition of Ga 68 chloride to the kit components in the reaction vial 3, use Gallium Ga 68 Gozetotide Injection within 4 hours. The final volume of the Gallium Ga 68 Gozetotide Injection is 7.5 mL.

Flow diagrams are provided for the radiosynthetic process to be followed at the radiopharmacy site for:

  • ILLUCCIX Configuration “A” when using Ga 68 prepared by cyclotron ( Figure 1) or
  • ILLUCCIX Configurations “A” or “B” when using an indicated GMP-grade EZAG GalliaPharm Ge 68/Ga 68 Generator ( Figure 2) or IRE Galli Eo Ge 68/Ga 68 Generator (Figure 3).

Figure 1: Preparation with Cyclotron Produced Ga 68 via GE FASTlab

Figure 1
(click image for full-size original)

Note: Ga 68 from GE FASTlab is aseptically transferred into the Sterile Vacuumed Reaction Vial.

Use “Configuration A” with cyclotron produced Ga 68 via GE FASTlab [ see How Supplied/Storage and Handling (16.1).

Figure 2: Preparation with Eckert & Ziegler GalliaPharm Generator

Figure 2
(click image for full-size original)

Note: Use “Configuration A” with EZAG GalliaPharm Ge 68/Ga 68 generator [ see How Supplied/Storage and Handling (16.1)] .

Figure 3 Preparation with IRE Galli Eo Generator

Figure 3
(click image for full-size original)

Note: Use “Configuration B” with IRE Galli Eo Ge 68/Ga 68 generator [ see How Supplied/Storage and Handling (16.1)] .

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.